about
Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cellsCytokine production associated with smallpox vaccine responsesEPIPOX: Immunoinformatic Characterization of the Shared T-Cell Epitome between Variola Virus and Related Pathogenic OrthopoxvirusesGenome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipientsHuman antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.Genomic expression libraries for the identification of cross-reactive orthopoxvirus antigens.The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 proteinGenome-wide genetic associations with IFNγ response to smallpox vaccineThe identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.Smallpox vaccines: targets of protective immunity.Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine.Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses.CD4+ T cell help is dispensable for protective CD8+ T cell memory against mousepox virus following vaccinia virus immunization.VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African Americans.Correlations between vaccinia-specific immune responses within a cohort of armed forces members.Immune modulation in primary vaccinia virus zoonotic human infectionsHuman immunodeficiency virus vaccinesSingle-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination.Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic miceThe Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-GlucoseCD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.Technical transformation of biodefense vaccines.MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.The strategic use of novel smallpox vaccines in the post-eradication world.Vaccination and the TAP-independent antigen processing pathways.Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines.Defending against smallpox: a focus on vaccines.Strategies for designing synthetic immune agonists.A viral, transporter associated with antigen processing (TAP)-independent, high affinity ligand with alternative interactions endogenously presented by the nonclassical human leukocyte antigen E class I molecule.Impaired innate, humoral, and cellular immunity despite a take in smallpox vaccine recipients.Preventing the return of smallpox: molecular modeling studies on thymidylate kinase from Variola virus.
P2860
Q24294775-A8E25F80-D331-4A14-B7AF-8DFC5E1AF5AAQ26823501-51D716C7-8094-40D8-B8CC-6AE75E6CD5CCQ28607584-7BE7677A-3744-4F61-A408-8425F9152F24Q28943252-E393AEDB-4B2C-4E59-BEA0-E4B0C10840BFQ33743444-AB45CF1F-4BE0-480F-9A48-D449E31667A7Q33892570-B8B26B46-2451-4B97-82CB-90745D84ECACQ33968161-E4285CA5-62B2-4AAD-9E58-749503F18026Q34039477-F6B7D4B1-1CE6-44D8-B225-7F3B8FC5932DQ34221936-56D5BC26-ABC4-4D86-97E5-24692F64EE61Q34288498-81E833B8-3D1E-49C0-B81A-D8299C3F6669Q34780607-57AF78A0-6C35-44F1-97E8-5460CA0F90FDQ34988328-BB822F74-F998-497C-BC5B-9BBB79E8E876Q34991389-F44DA1EF-8334-4F93-A2CB-C249EF0A8901Q34992708-15255F0E-33FF-4F2C-8565-8F487417BCBCQ35089019-023C8DF8-89F3-4B3E-8CF3-AA298C2E3FA7Q35093293-EBE8B8ED-1DD4-4C21-98E0-753B65BC68B2Q35608112-A7C09ECA-8D8D-4042-AD66-DF54BA347AFDQ35645804-2352A17F-161B-454D-B69A-AE5C3E2CABDCQ35674731-A446415A-44BD-4043-84C3-193662A79AF3Q35830974-4990C099-606E-476F-986A-7D54733BF459Q36330959-B586DCB7-46F0-4D7B-B815-B07F26BF7B26Q36580203-FB77AFC1-E2DF-4B18-B057-1C137C72D3B7Q36878858-EF769992-BB8E-42DA-9721-FAFA834AF25DQ36920299-87BAF1B3-D4C1-463B-AE45-6525F30501BEQ37058898-498E81A5-72D2-4E93-AD15-725757E44712Q37643755-340DB392-06B0-4639-8542-2535455500A4Q37791160-189DF702-04E0-46F9-8207-5EA52281ABDDQ37909421-60209B16-7C92-4266-8C72-FADDD81D381DQ38140044-DC222804-436B-433E-8460-CD6D39B0829BQ38543488-483BF8A6-FE7E-4BE3-8AD5-9D1F06A3D8A3Q38799357-BBF6B276-8751-4173-A971-25296D5F79B1Q38841677-92C3536D-0D2E-4A53-B47B-7D4FC77DF57CQ39289753-D7998EF0-EB0D-4CFE-A6FA-FD3F7180F12AQ40675201-5B296B0E-4570-40B6-B016-37B0A1120A22Q42272639-83C409A8-B40F-4A69-9172-C08DEF761448
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The immunology of smallpox vaccines.
@ast
The immunology of smallpox vaccines.
@en
type
label
The immunology of smallpox vaccines.
@ast
The immunology of smallpox vaccines.
@en
prefLabel
The immunology of smallpox vaccines.
@ast
The immunology of smallpox vaccines.
@en
P2860
P1476
The immunology of smallpox vaccines.
@en
P2093
Richard B Kennedy
Robert M Jacobson
P2860
P304
P356
10.1016/J.COI.2009.04.004
P577
2009-06-11T00:00:00Z